Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022
AUSTIN, Texas, Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows:
Conference: 40th Annual J.P. Morgan Health Care Conference, January 10-13, 2022
Conference: H.C. Wainwright Bioconnect Virtual Conference, January 10-13, 2022
To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company's website. A replay of Company webcasts is archived on the website for 30 days following presentations.
About Aeglea BioTherapeutics
View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-two-investor-conferences-in-january-2022-301453721.html
SOURCE Aeglea BioTherapeutics, Inc.
Company Codes: NASDAQ-NMS:AGLE
© 2022 PR Newswire. All Rights Reserved.